Smiths Medical receives exclusive USA rights to market PHASEIN’s emergency capnometer.

Thursday, 9 Nov, 2006

Smiths Medical Patient Monitoring and PHASEIN AB announced today that they have signed an agreement in which Smiths Medical receives exclusive USA rights to market PHASEIN’s emergency capnometer under the Smiths Medical CAPNOCHECK® label. PHASEIN will market the device in other markets under the brand name EMMA.

The EMMA™/Capnocheck® capnometer is the world’s first self-contained, real time quantitative capnometer for proof-of-intubation, spot-checking, and short-term CO2 monitoring of adults and children in emergency, transport, and acute care settings. EMMA™/ CAPNOCHECK®  is pending US FDA 510(k) clearance.

“This device equips the first responder and clinical professional with a pocket-sized quantitative capnometer suitable for high acuity settings,” said Ignacio Silva, Smiths Medical Patient Monitoring vice president of sales and marketing. “Capnocheck® is a significant breakthrough both clinically and economically in providing instantaneous respiratory data from intubated and non-intubated patients."

“As one of the world’s leading gas analysis companies, PHASEIN has an impressive track record in the development and marketing of innovative gas analyzers,” said Robert Zyzanski, CEO of PHASEIN. “We are confident that in Smiths Medical we have found a strong and committed partner for the launch of this novel capnometer in the US market.”

For more information, please contact 

Smiths Medical ASD, Inc.
600 Cordwainer Drive
Norwell, MA 02061
Ph: 214 618-0218 or 800 258-5361 (U.S.)

 www.smiths-medical.com.

About Smiths Medical
Smiths Medical PM, Inc. is a designer, manufacturer, and distributor of the BCI® brand of patient monitoring equipment and a distributor of the Pneupac® brand of MRI compatible transport ventilators.

VISIT US AT MEDICA 2006, BOOTH A37 HALL 9, November 15-19, Düsseldorf, Germany.


About PHASEIN

PHASEIN develops, manufactures and markets ultra-small gas monitoring probes, which can be integrated into patient monitors, anesthesia delivery systems, and ventilators. PHASEIN’s multi-gas probe IRMA is the size of an oximeter probe and thus overcomes the common shortfalls of traditional monitors. IRMA stands for convenience, mobility and ease of integration. The target groups for the IRMA probes are international medical equipment companies working within the fields of anesthesia, intensive care and emergency care. PHASEIN’s in-house tradition and expertise in developing gas analysis systems has resulted in the launch of the world’s smallest multi-gas analyzer – the IRMA probe and world’s first self-contained, Emergency Capnometer - EMMA. PHASEIN’s vision is summarized by the term: PLUG-IN and MEASURE.
Major investors in PHASEIN:

KAROLINSKA INVESTMENT FUND www.karolinskafund.com
SEB FÖRETAGSINVEST www.seb.se/foretagsinvest

VISIT US AT MEDICA 2006, BOOTH E47, HALL 11, November 15-19, Düsseldorf, Germany.

For more information, please contact:
Robert Zyzanski, CEO, phone: +46 8 544 98 166, +46 708 733 326
robert.zyzanski@phasein.se / www.phasein.se